Why the study?
Guidelines support aspirin thromboprophylaxis for primary total hip and knee arthroplasty, but supporting evidence has come from high-volume centers and the practice remains controversial.
Does aspirin alone prevent 30-day VTE as effectively as potent anticoagulants in Medicare patients undergoing elective primary total hip or knee arthroplasty?
Population
4562 Medicare patients undergoing elective primary THA or TKA at 9 hospitals
Comparison
Aspirin alone vs potent anticoagulant vs other antiplatelet/multiple anticoagulants vs heparin/no anticoagulation
Design
Retrospective cohort study
Follow-up
30 days
Authors
Loading...
Aspirin thromboprophylaxis in diverse hospitals needs prospective validation; leaves open generalizability of high-volume center outcomes to Medicare THA/TKA patients.
Does aspirin alone prevent 30-day VTE as effectively as potent anticoagulants in Medicare patients undergoing elective primary total hip or knee arthroplasty?
Aspirin alone provides equivalent 30-day VTE prophylaxis compared to potent anticoagulants following elective primary total hip or knee arthroplasty.
Matzko et al. (2021) studied this question.